TOPISCAB 5% (permethrin), antiparasitic
DERMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Apr 09 2015
Reason for request
Inclusion
Minor improvement in the management of human scabies
- TOPISCAB cream has Marketing Authorisation in the topical treatment of human scabies.
- Its efficacy has been demonstrated compared with orally administered ivermectin. It is based on compliance with two skin applications 1 week apart.
- This medicine can be used in children from 2 months of age and in pregnant women, populations not covered by the other currently available scabicides, in a context of an extended stock shortage of ASCABIOL. It offers a minor improvement in the treatment of human scabies.
Clinical Benefit
Substantial |
- |
Clinical Added Value
minor |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments